Duration of Antiresorptive Effects of Low-Dose Zoledronate in Osteopenic Postmenopausal Women: A Randomized, Placebo-Controlled Trial

Reduction in the Risk of Clinical Fractures After a Single Dose of Zoledronic Acid 5 Milligrams

(2013) I. R. Reid et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Five years of anti-resorptive activity after a single dose of zoledronate — Results from a randomized double-blind placebo-controlled trial

(2012) Andrew Grey et al.   BONE

Effects of Intravenous Zoledronate on Bone Turnover and Bone Density Persist for at Least Five Years in HIV-Infected Men

(2012) Mark J. Bolland et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)

(2011) Dennis M Black et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Low-Dose Zoledronate in Osteopenic Postmenopausal Women: A Randomized Controlled Trial

(2011) Andrew Grey et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

(2009) Steven R. Cummings et al.   NEW ENGLAND JOURNAL OF MEDICINE

Zoledronic Acid for the Prevention of Bone Loss in Postmenopausal Women With Low Bone Mass

(2009) Michael McClung et al.   OBSTETRICS AND GYNECOLOGY